PI3K/AKT/mTOR pathway, a critical pathway of treatment in HCC, is similarly involved in the activation of autophagy caused by combination of ATO/PTL, which provides possible directions for exploring the drugs aiming at this pathway, thereby enhancing the efficacy of ATO/PTL combination therapy. This evidence concerns the gene AKT1 and hepatocellular carcinoma.